Sugi Predict

Sugi Predict / Compounds / SCHEMBL388288

SCHEMBL388288

SCHEMBL388288

COC(=O)CC(N)c1ccc(C#N)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.60
▸ KCNA5 P22460 2/20 0.46
▸ MAPT P10636 4/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ CYP11B1 P15538 1/20 0.39
▸ CYP11B2 P19099 1/20 0.39
▸ EGLN1 Q9GZT9 1/20 0.39
▸ MMP2 P08253 1/20 0.39
▸ MMP3 P08254 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ CFD P00746 1/20 0.39
▸ RAB9A P51151 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ ADRB2 P07550 1/20 0.38
▸ ADRB1 P08588 1/20 0.38
▸ ADRB3 P13945 1/20 0.38
▸ TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL388289 1.00 HTT (0.60) HTTKCNA5MAPTKDM4EGAA
SCHEMBL27559396 0.84 HTT (0.47) HTTMAPTKDM4EGAAL3MBTL1
SCHEMBL22076577 0.83 HTT (0.62) HTTKCNA5MAPTKDM4EGAA
SCHEMBL24387800 0.82 KCNA5 (0.52) HTTKCNA5EGLN1ALDH1A1CFD
SCHEMBL5720880 0.82 HTT (0.43) HTTMAPTKDM4EGAAL3MBTL1
SCHEMBL13802839 0.80 RAB9A (0.56) HTTKCNA5MAPTGAAL3MBTL1
SCHEMBL5045992 0.80 ALDH1A1 (0.44) HTTMAPTL3MBTL1ALDH1A1RAB9A
SCHEMBL17167378 0.80 ALDH1A1 (0.44) HTTMAPTL3MBTL1ALDH1A1RAB9A
SCHEMBL13991118 0.80 KDM4E (0.55) HTTMAPTKDM4EGAAL3MBTL1
SCHEMBL23673364 0.80 ESR1 (0.46) HTTMAPTKDM4EALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12252495-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2025-03-18 — — US disclosed
US-20240109902-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2024-04-04 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-20200239483-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2020-07-30 — — US disclosed
US-10654855-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2020-05-19 — — US disclosed
US-20180312516-A1 Protein Kinase B Inhibitors ASTRAZENECA AB (SE) 2018-11-01 — — US disclosed
US-10059714-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2018-08-28 — — US disclosed
CN-104662015-B Complement pathway modulators and uses thereof 诺华股份有限公司 2017-03-29 — — CN disclosed
US-20170057969-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2017-03-02 — — US disclosed
US-9492453-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2016-11-15 — — US disclosed
US-20150182531-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2015-07-02 — — US disclosed
CN-104662015-A Complement pathway modulators and uses thereof NOVARTIS AG 2015-05-27 — — CN disclosed
CN-101861321-B Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors ASTRAZENECA AB 2013-02-06 — — CN disclosed
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2012-07-26 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
CN-101861321-A Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors ASTRAZENECA AB 2010-10-13 — — CN disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12252495-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 HTT 4164/4885KCNA5 1750/4885MAPT 3725/4885
US-20220220116-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 HTT 4164/4885KCNA5 1750/4885MAPT 3725/4885
US-20180312516-A1 Protein Kinase B Inhibitors PRKAR2B, PRKCB, AKT1 HTT 4164/4885KCNA5 1750/4885MAPT 3725/4885
US-10654855-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 HTT 4164/4885KCNA5 1750/4885MAPT 3725/4885
US-20240109902-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 HTT 4164/4885KCNA5 1750/4885MAPT 3725/4885
US-10059714-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 HTT 4164/4885KCNA5 1750/4885MAPT 3725/4885
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 HTT 4084/4885KCNA5 1688/4885MAPT 3597/4885
US-20170057969-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 HTT 4084/4885KCNA5 1688/4885MAPT 3597/4885
US-20200239483-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 HTT 4164/4885KCNA5 1750/4885MAPT 3725/4885
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 HTT 4084/4885KCNA5 1688/4885MAPT 3597/4885
US-11236095-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 HTT 4164/4885KCNA5 1750/4885MAPT 3725/4885
US-20150182531-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 HTT 4084/4885KCNA5 1688/4885MAPT 3597/4885
US-11760760-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 HTT 4164/4885KCNA5 1750/4885MAPT 3725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.